PT  - JOURNAL ARTICLE
AU  - M.R. Bonsignore
AU  - C. Esquinas
AU  - A. Barceló
AU  - M. Sanchez-de-la-Torre
AU  - A. Paternó
AU  - J. Duran-Cantolla
AU  - J.M. Marín
AU  - F. Barbé
TI  - Metabolic syndrome, insulin resistance and sleepiness in real-life obstructive sleep apnoea
AID  - 10.1183/09031936.00151110
DP  - 2011 Jan 01
TA  - European Respiratory Journal
PG  - erj01511-2010
4099  - http://erj.ersjournals.com/content/early/2011/11/09/09031936.00151110.short
4100  - http://erj.ersjournals.com/content/early/2011/11/09/09031936.00151110.full
AB  - The Metabolic Syndrome shows a variable prevalence in obstructive sleep apnoea (OSA), and its association with insulin resistance or excessive daytime sleepiness in OSA is unclear. This study assessed in consecutive patients with newly diagnosed OSA: 1) the prevalence of Metabolic Syndrome, and 2) its association with insulin resistance and daytime sleepiness.Metabolic Syndrome (NCEP-ATP III criteria), insulin resistance (Homeostatic Model Assessment Index, n= 288) and daytime sleepiness (Epworth Sleepiness Scale) were assessed in 529 OSA patients.Prevalence of Metabolic Syndrome was 51.2%, and increased with OSA severity. Each Metabolic Syndrome component correlated with AHI, but only blood pressure retained significance after correction for confounders. Both obesity and OSA contributed to metabolic abnormalities, with different gender-related patterns, since diagnosis of MetS was significantly associated with neck circumference, age BMI, and lowest Sa,O2 in males, and with age and arousal index in females. The number of MetS components increased with HOMA Index (p<0.0001). Prevalence of sleepiness was the same in patients with and without Metabolic Syndrome.The Metabolic Syndrome occurs in about half of “real life” OSA patients irrespective of daytime sleepiness, and is a reliable marker of insulin resistance.